Santhera Pharmaceuticals Holding AG
SANN
Pozycja w akcjach
#16115
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Cena akcji
$19.25
Kapitalizacja rynkowa
$294.54M
Zmiana (1 dzień)
2.64%
Zmiana (1 rok)
48.09%
Kraj
CH
Handel Santhera Pharmaceuticals Holding AG (SANN)
Kategoria
Healthcare
Historia stopy dywidendy dla Santhera Pharmaceuticals Holding AG (SANN)
Stopa dywidendy (TTM) dla Santhera Pharmaceuticals Holding AG (symbol akcji: SANN) na dzień 2026 wynosi: 0
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Średnia stopa dywidendy z ostatnich 5 lat: 0.00%
Historia stopy dywidendy dla Santhera Pharmaceuticals Holding AG (SANN) od 2026 do 2026
Stopa dywidendy na koniec każdego roku (TTM)
| Rok | Stopa dywidendy | Zmień |
|---|---|---|
| Za mało danych dla podanych dat. | ||
Stopy dywidendy (TTM) dla podobnych firm lub konkurencji
| Firma | Stopa dywidendy | Kraj |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
